ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Edith Perez on Etirinotecan Pegol for HER2-Negative Breast Cancer

Edith A. Perez, MD
Published: Thursday, Jan 22, 2015



Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.
 
The BEACON trial (BrEAst Cancer Outcomes with NKTR-102) is an important study for refractory HER2-negative breast cancer, says Perez. It looks at the new compound etirinotecan pegol (NKTR-102), a long-acting topoisomerase-1 inhibitor designed for prolonged tumor cell exposure, in comparison to physicians’ choice of treatment. 


Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.
 
The BEACON trial (BrEAst Cancer Outcomes with NKTR-102) is an important study for refractory HER2-negative breast cancer, says Perez. It looks at the new compound etirinotecan pegol (NKTR-102), a long-acting topoisomerase-1 inhibitor designed for prolonged tumor cell exposure, in comparison to physicians’ choice of treatment. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x